This podcast is not purely focused on the viral vector lentivirus, but the wider context in which this critical material sits within the wider cell and gene therapy and bioproduction space.
Andy Lewin and Adam Inche will be joined each week by special guests to discuss a diverse range of topics associated with, but not limited to the use of lentiviral vectors in the cell and gene therapy space.
Its a podcast mashup as we are joined by Ben McLeod and Jeff Martin of Bio2Bedside fame!
Three big themes in this episode:
Adam and Andy are joined by Dr Gerry McLachlan from the Roslin Institute at the University of Edinburgh. Simon Boa, General Manager at Bramble Bio, a leading European cell therapy CDMO also joins us.
In the podcast we chat about lentivirus based CF gene therapies and competition for patients. The commercial outlook for CGT, with an analysis of the clinical pipeline. The rise of China and India as CGT powerhouses.
We also chat about meeting Dolly the Sheep and cupcakes!
In this short episode Adam and Andy are joined by internet sensation (and Yorkshireman) Spencer Knight!
We chat about why the advanced therapies industry should be optimistic and how the Trogenix investment of £70 million (about $90 million USD) is a great sign for European biotech and that it should be celebrated.
In this episode Adam Inche and Andy Lewin are joined by Tom Klenka to discuss a number of topics including:
1) Introduction to the podcast name and artwork
2) What is the concept behind Lenti with Friends
3) How is sales different in a service providing environment
4) 50 years of mAbs and what this can teach us for viral vector manufacturing
5) Why are viral vector CDMOs struggling and closing their doors?
Copyright © 2025 Lentitek Ltd - All Rights Reserved.